Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-26T22:05:48.411Z Has data issue: false hasContentIssue false
  • English
  • Français

The role of N-terminal pro-brain natriuretic peptide (NT-pro-BNP) as a prognostic marker in older people: the impact of reduced renal function

Part of: Bespoke shallow archive Weizmann

Published online by Cambridge University Press:  17 September 2009

Thiane Gama Axelsson  and
Bengt Lindholm
Thiane Gama Axelsson
Affiliation:
Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
Bengt Lindholm*
Affiliation:
Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden
*
Address for correspondence: Bengt Lindholm, Division of Renal Medicine K56, Karolinska University Hospital at Huddinge, 141 86 Stockholm, Sweden. Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Summary

The N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is released in response to volume expansion and/or increased tension on left ventricular myocytes. NT-pro-BNP is a useful diagnostic and prognostic biomarker both in patients with dyspnoea of unknown aetiology, and for risk assessment of patients with established heart failure. However, impaired kidney function – a common condition in older people as well as a strong risk factor for cardiovascular disease is associated with elevated circulating levels of NT-pro-BNP. Therefore, it is important to know the kidney function when interpreting an elevated NT-pro-BNP measurement obtained in older people in order to diagnose or stage congestive heart failure.

Keywords

Brain natriuretic peptideolder peoplerenal functioncongestive heart failure
Type
Biological gerontology
Information
Reviews in Clinical Gerontology , Volume 19 , Issue 2 , May 2009 , pp. 71 - 76
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Hall, C. NT-ProBNP: the mechanism behind the marker. J Card Fail 2005; 11: 81–83.CrossRefGoogle ScholarPubMed
2Hall, C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6: 257–60.CrossRefGoogle ScholarPubMed
3Kuhn, M. Cardiac and intestinal natriuretic peptides: insights from genetically modified mice. Peptides 2005; 26: 1078–1085.CrossRefGoogle ScholarPubMed
4Martinez-Rumayor, A, Richards, AM, Burnett, JC and Januzzi, JL Jr.Biology of the natriuretic peptides. Am J Cardiol 2008; 101: 3–8.CrossRefGoogle ScholarPubMed
5Khalifeh, N, Haider, D, Horl, WH. Natriuretic peptides in chronic kidney disease and during renal replacement therapy: an update. J Investig Med 2009; 57: 33–39.CrossRefGoogle ScholarPubMed
6Maisel, AS, Bhalla, V, Braunwald, E. Cardiac biomarkers: a contemporary status report. Nat Clin Pract Cardiovasc Med 2006; 3: 24–34.CrossRefGoogle ScholarPubMed
7Coresh, J, Selvin, E, Stevens, LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007; 298: 2038–47.CrossRefGoogle ScholarPubMed
8Cowie, MR, Mosterd, A, Wood, DA et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208–225.CrossRefGoogle ScholarPubMed
9Zolty, R, Hynes, PJ, Vittorio, TJ. Severe left ventricular systolic dysfunction may reverse with renal transplantation: uremic cardiomyopathy and cardiorenal syndrome. Am J Transplant 2008; 8: 2219–24.CrossRefGoogle ScholarPubMed
10Yildiz, O. Vascular smooth muscle and endothelial functions in aging. Ann N Y Acad Sci 2007; 1100: 353–360.CrossRefGoogle ScholarPubMed
11Denys, K, Cankurtaran, M, Janssens, W, Petrovic, M. Metabolic syndrome in the elderly: an overview of the evidence. Acta Clin Belg 2009; 64: 23–34.CrossRefGoogle ScholarPubMed
12Ikizler, TA. Epidemiology of vascular disease in renal failure. Blood Purif 2002; 20: 6–10.CrossRefGoogle ScholarPubMed
13Berl, T, Henrich, W. Kidney–heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol 2006; 1: 8–18.CrossRefGoogle ScholarPubMed
14Csiszar, A, Toth, J, Peti-Peterdi, J, Ungvari, Z. The aging kidney: role of endothelial oxidative stress and inflammation. Acta Physiol Hung 2007; 94: 107–15.CrossRefGoogle ScholarPubMed
15Wang, X, Keith, JC Jr, Struthers, AD, Feuerstein, GZ. Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther 2008; 26: 214–23.CrossRefGoogle ScholarPubMed
16Manjunath, G, Tighiouart, H, Coresh, J et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121–29.CrossRefGoogle ScholarPubMed
17Freedman, BI, Langefeld, CD, Lohman, KK et al. Relationship between albuminuria and cardiovascular disease in Type 2 diabetes. J Am Soc Nephrol 2005; 16: 2156–61.CrossRefGoogle ScholarPubMed
18Acton, RT, Go, RC, Roseman, JM. Genetics and cardiovascular disease. Ethn Dis 2004; 14: S2–8-16.Google ScholarPubMed
19Anavekar, NS, Pfeffer, MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; suppl S11–15.CrossRefGoogle Scholar
20Shlipak, MG, Massie, BM. The clinical challenge of cardiorenal syndrome. Circulation 2004; 110: 1514–17.CrossRefGoogle ScholarPubMed
21Ix, JH, Shlipak, MG, Liu, HH, Schiller, NB, Whooley, MA. Association between renal insufficiency and inducible ischemia in patients with coronary artery disease: the heart and soul study. J Am Soc Nephrol 2003; 14: 3233–38.CrossRefGoogle ScholarPubMed
22Christenson, RH. What is the value of B-type natriuretic peptide testing for diagnosis, prognosis or monitoring of critically ill adult patients in intensive care? Clin Chem Lab Med 2008; 46: 1524–32.CrossRefGoogle ScholarPubMed
23Vickery, S, Price, CP, John, RI et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46: 610–20.CrossRefGoogle ScholarPubMed
24Tagore, R, Ling, LH, Yang, H, Daw, HY, Chan, YH, Sethi, SK. Natriuretic peptides in chronic kidney disease. Clin J Am Soc Nephrol 2008; 3: 1644–51.CrossRefGoogle ScholarPubMed
25Hartmann, F, Packer, M, Coats, AJ et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 2004; 110: 1780–86.CrossRefGoogle ScholarPubMed
26Mayer, O Jr, Simon, J, Plaskova, M, Cifkova, R, Trefil, L. N-terminal pro B-type natriuretic peptide as a prognostic marker for mortality in coronary patients without clinically manifest heart failure. Eur J Epidemiol 2009; 24: 363–8.CrossRefGoogle ScholarPubMed
27Masson, S, Latini, R, Anand, IS et al. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006; 52: 1528–38.CrossRefGoogle Scholar
28Kragelund, C, Gronning, B, Kober, L, Hildebrandt, P, Steffensen, R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352: 666–75.CrossRefGoogle ScholarPubMed
29Lamba, S, Abraham, WT. Alterations in adrenergic receptor signaling in heart failure. Heart Fail Rev 2000; 5: 7–16.CrossRefGoogle ScholarPubMed
30Wu, AH. Plasma BNP/NT-proBNP assays: what do they target and what else might they recognize? Heart Fail Clin 2006; 2: 291–98.CrossRefGoogle ScholarPubMed
31Green, SM, Green, JA, Januzzi, JL Jr.Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting. Am J Ther 2009; 16: 171–77.CrossRefGoogle ScholarPubMed
32Januzzi, JL, van Kimmenade, R, Lainchbury, J et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27: 330–37.CrossRefGoogle Scholar
33O'Donoghue, M, Chen, A, Baggish, AL et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Card Fail 2005; 11: S9–14.CrossRefGoogle ScholarPubMed
34Chen, AA, Wood, MJ, Krauser, DG et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur Heart J 2006; 27: 839–45.CrossRefGoogle ScholarPubMed
35Weber, M, Arnold, R, Rau, M et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur Heart J 2005; 26: 1023–30.CrossRefGoogle ScholarPubMed
36Morello, A, Lloyd-Jones, DM, Chae, CU et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 2007; 153: 90–97.CrossRefGoogle ScholarPubMed
37Foote, RS, Pearlman, JD, Siegel, AH, Yeo, KT. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 2004; 44: 1980–87.CrossRefGoogle ScholarPubMed
38Khan, IA, Fink, J, Nass, C, Chen, H, Christenson, R, deFilippi, CR. N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol 2006; 97: 1530–34.CrossRefGoogle ScholarPubMed
39Takami, Y, Horio, T, Iwashima, Y et al. Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis 2004; 44: 420–28.CrossRefGoogle ScholarPubMed
40Madsen, LH, Ladefoged, S, Corell, P, Schou, M, Hildebrandt, PR, Atar, D. N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysis. Kidney Int 2007; 71: 548–54.CrossRefGoogle ScholarPubMed
41Satyan, S, Light, RP, Agarwal, R. Relationships of N-terminal pro-B-natriuretic peptide and cardiac troponin T to left ventricular mass and function and mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 50: 1009–19.CrossRefGoogle ScholarPubMed
42Sommerer, C, Beimler, J, Schwenger, V et al. Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest 2007; 37: 350–56.CrossRefGoogle ScholarPubMed
43Palmer, SC and Richards, AM. Does renal clearance differ between the B-type natriuretic peptides (BNP versus NT-proBNP)? J Am Coll Cardiol 2009; 53: 891–92.CrossRefGoogle ScholarPubMed
44DeFilippi, C, van Kimmenade, RR, Pinto, YM. Amino-terminal pro-B-type natriuretic peptide testing in renal disease. Am J Cardiol 2008; 101: 82–88.CrossRefGoogle ScholarPubMed
45Zoccali, C, Mallamaci, F, Benedetto, FA et al. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508–15.CrossRefGoogle ScholarPubMed
46Wang, AY, Lai, KN. Use of cardiac biomarkers in end-stage renal disease. J Am Soc Nephrol 2008; 19: 1643–52.CrossRefGoogle ScholarPubMed
47Wang, TJ, Larson, MG, Levy, D et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254–58.CrossRefGoogle ScholarPubMed
48Raizada, V, Thakore, K, Luo, W, McGuire, PG. Cardiac chamber-specific alterations of ANP and BNP expression with advancing age and with systemic hypertension. Mol Cell Biochem 2001; 216: 137–40.CrossRefGoogle ScholarPubMed
49Taylor, JA, Christenson, RH, Rao, K, Jorge, M, Gottlieb, SS. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006; 152: 1071–76.CrossRefGoogle ScholarPubMed
50Davidoff, AJ, Powe, NR. The role of perspective in defining economic measures for the evaluation of medical technology. Int J Technol Assess Health Care 1996; 12: 9–21.CrossRefGoogle ScholarPubMed
51Drewniak, W, Snopek, G, Zarukiewicz, M, Borys, M, Dabrowski, M. Prognostic value of the N-terminal pro-B-type natriuretic peptide in the elderly with acute myocardial infarction. Kardiol Pol 2008; 66: 750–55; discussion 756–57.Google ScholarPubMed
52Clark, BA, Elahi, D, Shannon, RP, Wei, JY, Epstein, FH. Influence of age and dose on the end-organ responses to atrial natriuretic peptide in humans. Am J Hypertens 1991; 4: 500–7.CrossRefGoogle ScholarPubMed
53Giannessi, D, Andreassi, MG, Del Ry, S, Clerico, A, Colombo, MG, Dini, N. Possibility of age regulation of the natriuretic peptide C-receptor in human platelets. J Endocrinol Invest 2001; 24: 8–16.CrossRefGoogle ScholarPubMed
54Das, SR, Abdullah, SM, Leonard, D et al. Association between renal function and circulating levels of natriuretic peptides (from the Dallas Heart Study). Am J Cardiol 2008; 102: 1394–98.CrossRefGoogle ScholarPubMed